权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Using Sleep Health to Optimize Smoking Cessation Treatment Response in HIV-Positive Adults

利用睡眠健康来优化艾滋病毒阳性成人的戒烟治疗反应

基本信息

批准号：
10618603
负责人：
Elizabeth Connick
金额：
$ 10.9万
依托单位：
UNIVERSITY OF ARIZONA
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-07-01 至 2025-05-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10618603
关键词：
Adherence Adult Affect Affective Biochemical Biological Markers Blood Pressure Cardiovascular Diseases Cognition Cognitive Cotinine Counseling Development Exhalation Expectancy Female General Population Goals HIV HIV Seropositivity HIV-1 Health Health education Infection Intervention K-Series Research Career Programs Link Literature Measures Mediating Mentorship Morbidity - disease rate Outcome Participant Pathway interactions Pattern Pharmacotherapy Pilot Projects Population Public Health Questionnaires Race Randomized Randomized Controlled Trials Relapse Reporting Research Research Training Risk Factors Role Sample Size Sampling Severities Sleep Sleeplessness Smoker Smoking Smoking Cessation Intervention Smoking and Health Research Training Treatment Efficacy Urine Withdrawal acceptability and feasibility actigraphy aged base cardiovascular disorder risk cardiovascular health cardiovascular risk factor cigarette smoking comorbidity design diaries efficacy evaluation efficacy testing evidence base experience improved indexing insight interest male mortality novel parent grant poor sleep programs prospective test recruit relapse prediction sleep health smoking cessation smoking intervention success treatment response varenicline

项目摘要

Abstract Parent Grant: Cardiovascular disease (CVD) is a major cause of morbidity and mortality in adults living with HIV (ALHIV), and cigarette smoking is the single most important modifiable CVD risk factor in this population. Success rates for existing smoking cessation interventions are relatively low. Poor sleep is more prevalent among smokers, more prevalent among ALHIV, can be caused by smoking cessation attempts, predicts relapse to former smoking patterns, and represents a parallel pathway to morbidity including increased cardiovascular disease (CVD) among ALHIV. Thus, unhealthy sleep may make smoking cessation more difficult and increase cardiovascular risk and other poor health conditions in ALHIV. Yet, poor sleep is amenable to nonpharmacologic interventions, and a pilot study from our group revealed that a sleep health intervention increased smoking cessation rates when added to routine smoking cessation treatment. To evaluate the efficacy of our sleep training approach to improve sleep health and increase smoking cessation rates in ALHIV, the proposed study will supplement an empirically-supported smoking cessation program (6- session, 15-week counseling program with varenicline) with a Sleep Training Approach to Reducing Smoking (STARS) intervention developed for smokers. STARS will be compared to a General Health (GH) educational control. The study will recruit N=200 ALHIV smokers who are interested in quitting. They will be randomized to smoking cessation with either STARS (N=100) or GH (N=100). The study will measure the efficacy of STARS versus GH to improve objectively measured healthy sleep metrics, assess its impact on smoking cessation as well as other metrics of CVD risk, and determine whether cognitive and affective variables mediate the association between sleep health and smoking cessation. Results of these studies will provide practical information as well as mechanistic insight into how sleep health can be leveraged to optimize smoking cessation treatment in ALHIV. Supplement: This diversity supplement includes research and training components. The training component will provide the candidate with the mentorship and development experiences necessary to successfully compete for a K award application. The research component will recruit intervention non-responders into a novel smoking and sleep intervention based on Acceptance and Commitment Therapy (ACT). Research aims of the supplement include (1) Determine the feasibility and acceptability of the intervention in non-responder ALHIV, and (2) Determine the preliminary efficacy of the intervention for smoking cessation rates, sleep health, and cardiovascular health. .

摘要